Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

A spike protein S2 antibody efficiently neutralizes the Omicron variant

Cellular & Molecular Immunology volume 19, pages 644–646 (2022)Cite this article

Subjects

A Correction to this article was published on 16 January 2025

This article has been updated

Access through your institution
Buy or subscribe

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant B.1.1.529, also named Omicron, is becoming the main circulating strain in many countries worldwide and brings new challenges to preventing COVID-19 [1,2,3,4,5]. The latest data show that the Omicron variant contains more than 50 mutations. Among them, there are 32 mutations in the spike protein [6], which is the key component that determines the infectivity and antigenicity of the virus. Furthermore, 15 mutations are located in the receptor-binding domain (RBD), which is key for viral-cell interactions mediated by angiotensin-converting enzyme 2 (ACE-2) [7, 8]. Due to the large number of mutations, especially in the RBD domain, there is concern that the Omicron variant can escape antibody neutralization induced by the current coronavirus disease 2019 (COVID-19) vaccines or neutralizing antibodies. This concern is supported by the fact that the Omicron variant exhibits significantly more neutralization resistance [2,3,4, 9]. In particular, RBD mutations are most prevalent. As reported previously, the RBD region of the S1 protein plays a critical role in novel coronavirus-infected cells, directly binding to the host receptor ACE2 [7, 8]. Therefore, almost all neutralizing antibodies have been designed to target the S1 protein [10]. However, in addition to the S1 subunit, the SARS-CoV-2 surface S protein comprises the S2 subunit, which mediates viral cell membrane fusion, though the probability of mutation in the S2 region is relatively low [11]. Based on these findings, we screened and validated S2 protein antibodies against the Omicron variant and explored the possibility of developing an S2 antibody to protect against SARS-CoV-2 variants.

Antibody phage/yeast display libraries are a powerful tool for generating human antibodies against tumors and infectious diseases [12,13,14]. Previously, we successfully used this technology to develop diagnostic and therapeutic reagents against a series of tumor targets [15, 16] and neutralizing antibodies against the RBD and NTD of SARS-CoV-2 (unpublished data). In this work, we screened a specific scFv against spike protein S2 of SARS-CoV-2. By validating specific binding with S2 and neutralization of Omicron pseudovirus, we identified an S2-specific antibody, HCLC-031, that efficiently neutralizes the Omicron variant in vitro. Our findings indicate that the S2 subunit is a potential target for the development of neutralizing antibodies and vaccines against SARS-CoV-2 Omicron.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Change history

  • 09 January 2025

    The original online version of this article was revised: In the Funding information section of this article the grant number relating to author Xiang Chen was omitted and should have been Sichuan Science and Technology Program (grant No. 2022JDRC0060). The original article has been corrected.

  • 16 January 2025

    A Correction to this paper has been published: https://doi.org/10.1038/s41423-025-01255-0

References

  1. Chen J, Wang R, Gilby NB, Wei GW. Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022;62:412–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, et al. Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol. 2022;94:1738–44.

    Article  CAS  PubMed  Google Scholar 

  3. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv. 2021:2021.12.08.21267417.

  4. Cui, Z, Liu P, Wang N, Wang L, Fan K, Zhu Q, et al. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 2022;185:860–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gu H, Krishnan P, Ng D, Chang L, Liu G, Cheng S, et al. Probable transmission of SARS-CoV-2 omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg Infect Dis. 2022;28:460–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ma W, Yang J, Fu H, Su C, Yu C, Wang Q, et al. Genomic perspectives on the emerging SARS-CoV-2 omicron variant. Genomics Proteom Bioinforma. 2022;1:33.

    Google Scholar 

  7. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181:894–904 e899.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021;602:657–63.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharm Sci. 2020;41:815–29.

    Article  CAS  PubMed  Google Scholar 

  11. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1339–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 1996;14:309–14.

    Article  CAS  PubMed  Google Scholar 

  13. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JMW, Yeung YA, et al. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat Biotechnol. 2003;21:163–70.

    Article  CAS  PubMed  Google Scholar 

  14. Scholler N, Gross JA, Garvik B, Wells L, Liu Y, Loch CM, et al. Use of cancer-specific yeast-secreted in vivo biotinylated recombinant antibodies for serum biomarker discovery. J Transl Med. 2008;6:41.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yuan X, Yang M, Chen X, Zhang X, Sukhadia S, Musolino N, et al. Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy. Cancer Immunol Immunother. 2017;66:367–78.

    Article  CAS  PubMed  Google Scholar 

  16. Li C, Wang J, Hu J, Feng Y, Hasegawa K, Peng X, et al. Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget. 2014;5:6994–7012.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Sichuan Science and Technology Program (grant No. 2019YFS0111 and 2022JDRC0060); the PostDoctor Research Project, West China Hospital, Sichuan University (No. 2020HXBH131); the National Science Foundation of China (No. 82103413); the PostDoctor Research Project of Sichuan University and Sichuan University postdoctoral interdisciplinary Innovation Fund (to Lingling Zhu); and the Key R & D projects of Science and Technology Department of Sichuan (grant No. 2020YFS0212).

Author information

Author notes

  1. These authors contributed equally: Jia Hu, Xiang Chen, Xingbing Lu.

Authors and Affiliations

  1. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China

    Jia Hu, Liyuan Yin, Lingling Zhu, Hao Liang, Feng Xu & Qinghua Zhou

  2. Institute for Immunology, Tsinghua University, Beijing, China

    Xiang Chen

  3. Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China

    Xingbing Lu & Lijuan Wu

Authors
  1. Jia Hu
    View author publications

    Search author on:PubMed Google Scholar

  2. Xiang Chen
    View author publications

    Search author on:PubMed Google Scholar

  3. Xingbing Lu
    View author publications

    Search author on:PubMed Google Scholar

  4. Lijuan Wu
    View author publications

    Search author on:PubMed Google Scholar

  5. Liyuan Yin
    View author publications

    Search author on:PubMed Google Scholar

  6. Lingling Zhu
    View author publications

    Search author on:PubMed Google Scholar

  7. Hao Liang
    View author publications

    Search author on:PubMed Google Scholar

  8. Feng Xu
    View author publications

    Search author on:PubMed Google Scholar

  9. Qinghua Zhou
    View author publications

    Search author on:PubMed Google Scholar

Contributions

HJ designed and performed the experiments and wrote the manuscript. CX designed the experiments, analyzed the data and wrote the manuscript; LXB performed parts of the experiments and analyzed the data. WLJ, YLY and ZLL participated in parts of the experiments. LH assisted with data analysis. XF and ZQH supervised this study and edited the manuscript.

Corresponding authors

Correspondence to Jia Hu or Qinghua Zhou.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

The original online version of this article was revised: In the Funding information section of this article the grant number relating to author Xiang Chen was omitted and should have been Sichuan Science and Technology Program (grant No. 2022JDRC0060). The original article has been corrected.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, J., Chen, X., Lu, X. et al. A spike protein S2 antibody efficiently neutralizes the Omicron variant. Cell Mol Immunol 19, 644–646 (2022). https://doi.org/10.1038/s41423-022-00847-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41423-022-00847-4

This article is cited by

Search

Advanced search

Quick links